If you have PMOS (PCOS) and you’ve been anywhere near the internet lately, you’ve seen the conversation. GLP-1 receptor agonists - the class of medicines that includes Ozempic and Mounjaro - have gone from diabetes clinics to dinner-table conversation in about two years. And because weight and insulin resistance sit near the centre of many women’s PMOS experience, the question lands quickly: should I be on one of these?
Let’s be clear about what this article is not. It’s not a review of these medicines. It won’t compare one to another, tell you whether they work for PMOS, or discuss doses. Those are conversations for a doctor who knows your case - and that’s precisely the point.
Why this decision deserves more scrutiny, not less
The evidence for PMOS specifically is still evolving. These medicines were developed and approved for type 2 diabetes and, later, weight management. PMOS-specific research is active but younger, and international PMOS guidance is still catching up to the pace of public interest. When a treatment category is moving this fast, the gap between headline and guideline is where individual medical advice matters most.
“It worked for her” is not a treatment plan. PMOS has four distinct phenotypes, and insulin resistance - the mechanism most discussed in this conversation - varies enormously between women. Whether any metabolic treatment even targets your version of the condition is a question that starts with your labs, not with someone else’s transformation post.
The practical stakes are real. These are typically long-term, injectable, expensive medicines - in India, the monthly cost can rival a salary. Studies consistently show that weight regain after stopping is common, which makes “how long would I be on this, and what’s the exit plan?” a first-date question, not an afterthought.
Timing matters enormously if pregnancy is anywhere on your horizon. These medicines are not recommended during pregnancy or while actively trying to conceive. For a condition so intertwined with fertility, that single fact reshapes the whole decision for many women - and it’s exactly the kind of thing that should be discussed with a specialist who knows your plans, not discovered later.
“The faster a treatment category moves, the more your decision should rest on your own labs - not the loudest success story.”
The questions a specialist would actually ask
Before any conversation about this class of medicines, a thorough specialist would want to know: Has your insulin resistance actually been measured - with an OGTT (a two-hour glucose test) and insulin levels, not just fasting sugar? Which phenotype are you? What have you already tried, and what did it do? What are your fertility plans over the next two to three years? Are there other conditions or medicines in the picture? What does your budget realistically sustain, for how long?
Notice that every one of those questions is about you, not the drug. If nobody has asked them yet, the decision isn’t ready to be made - in either direction.
This cuts both ways. A specialist’s review isn’t a gatekeeping exercise designed to talk you out of anything. It may confirm the option is worth discussing with your treating doctor. The goal is that whatever you decide, you decide it with your own complete picture in front of you.
Ozempic vs Mounjaro for PCOS: what actually differs
Both are prescription injections originally approved for type-2 diabetes and now widely used off-label in PCOS-related weight and insulin issues. They aren’t the same drug, and the choice between them isn’t just about which one your friend’s clinic stocks.
- Ozempic (semaglutide) is a single-receptor GLP-1 agonist. Weekly injection. The most published PCOS-adjacent data sits here, mostly on weight, HbA1c and insulin sensitivity.
- Wegovy (semaglutide, higher dose) is the same molecule as Ozempic at a weight-loss dose. Approved for obesity, not diabetes.
- Mounjaro (tirzepatide) is a dual GIP + GLP-1 agonist. Weekly injection. Head-to-head trials in obesity have shown larger average weight loss than semaglutide, with a similar GI side-effect profile.
What people usually want to know:
- Weight loss: tirzepatide (Mounjaro) has produced larger average reductions than semaglutide (Ozempic/Wegovy) in obesity trials. PCOS-specific head-to-head evidence is still thin.
- Insulin resistance: both improve fasting insulin and HOMA-IR when they drive meaningful weight loss. The mechanism is largely mediated by weight change, so the drug that you can actually sustain often matters more than the pharmacology.
- Cycle regularity and ovulation: improvements are reported for both, largely downstream of weight loss and improved insulin sensitivity. Not a stated indication for either drug.
- Fertility plans: both are stopped at least 2 months before trying to conceive. If a pregnancy is planned in the next year, that changes the calculus for both.
- Side effects: similar class effects — nausea, reflux, constipation, occasional gallbladder issues. Titration schedule and how your body tolerates each one is very individual.
- Cost & access in India: availability, price and reimbursement differ meaningfully month to month. What’s cheaper today may not be next quarter.
The honest answer to “Ozempic or Mounjaro for PCOS?” is: it depends on your phenotype, your metabolic labs, your fertility timeline, what side effects you can tolerate, and what you can sustain financially over 12–24 months. None of those are answerable from a headline.
Where a second opinion fits
Maybe your doctor has suggested one of these medicines and you want an independent read before starting. Maybe you’re curious but your current care hasn’t looked at your metabolic labs in years. Either way, the move is the same: get your full case - cycle history, androgens, metabolic tests, goals - in front of a specialist, and let the conversation start from evidence. TheSecondMD doesn’t prescribe, and doesn’t need to. What we do is make sure that when you and your treating doctor make this call, you’re making it fully informed.